about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Biotech short sell­er lands on fed­s' watch list amid sweep­ing probe — re­port

4 years ago
People

Pfiz­er scoops up Are­na and its S1P drug in $6.7B buy­out — chas­ing Bris­tol My­ers and cap­ping a lengthy biotech ...

4 years ago
Deals

End­points hon­ors 20 women su­per­charg­ing drug R&D; Omi­cron is a 'stress test' for the next pan­dem­ic; Roche and ...

4 years ago
Weekly

Video: Hear from End­points' 2021 Women in Bio­phar­ma R&D hon­orees and lis­ten in on our pan­el dis­cus­sion on break­ing ...

4 years ago
Special

Vi­vo Cap­i­tal, Bain, Pri­mav­era pour $200M in­to vir­tu­al­ly un­known tar­get­ed on­col­o­gy play out of Chi­na

4 years ago
Financing
China

As­traZeneca grabs PhI­II AT­TR drug from Io­n­is — in­fus­ing $200M cash in­to strug­gling part­ner

4 years ago
Deals

Covid-19 roundup: Val­ne­va de­fends vac­cine in wake of un­flat­ter­ing boost­er study; Mer­ck goes af­ter Pfiz­er’s new ...

4 years ago
Coronavirus

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at ...

4 years ago
Weekly

In­mate who posed as Ab­b­Vie pur­chas­ing of­fi­cer in $3M scam sen­tenced to 7 more years of prison

4 years ago
People

Watch out, Roche: No­var­tis inks $1.5B deal to chase down promi­nent Parkin­son’s tar­get

4 years ago
Deals

Bob Nelsen woos John Maraganore to his first VC post af­ter re­tir­ing from Al­ny­lam

4 years ago
People

Chi­na boasts 48% price cut on in­sulin as do­mes­tic drug­mak­ers eclipse Big Phar­ma in bulk or­der

4 years ago
China
Pharma

Sanofi snaps up new vac­cine can­di­date and de­vis­es mR­NA game plan around it — but not for what you think

4 years ago
Deals
Cell/Gene Tx

As lead drug runs in­to a wall, De­ci­phera slims down its pipeline, puts 140 jobs on the chop­ping block

4 years ago
People
R&D

Chi­na’s top mR­NA con­tender is ready to go. And Soft­Bank just led a cash in­fu­sion push­ing it over the $1B line

4 years ago
Financing
China

Nev­er too late: For­bion pitch­es $100M SPAC; Kro­nos Bio re­leas­es ear­ly in­ter­im da­ta on CDK9 in­hibitor

4 years ago
News Briefing

Eu­ro­pean in­vestors pour $156M to beat Blue­stone, Third Rock and RA Cap­i­tal in multi­bil­lion-dol­lar race to the clin­ic

4 years ago
Financing
Cell/Gene Tx

Thanks­giv­ing edi­tion: Top 15 End­points sto­ries of 2021; Can you name that vac­cine?; Mer­ck­'s Covid an­tivi­ral ...

4 years ago
Weekly

BeiGene gets the ball rolling on its 3rd IPO — and this one is ex­pect­ed to fetch $3B

4 years ago
Financing
China

$107B in 2+ years? Pfiz­er’s Covid-19 vac­cine may re­de­fine ‘megablock­buster’ by 2022 — an­a­lyst

4 years ago
Pharma
Coronavirus

Eight years and $1.3B lat­er, As­traZeneca fi­nal­ly un­veils Cam­bridge R&D palace

4 years ago
Pharma

Two of Chi­na's top PD-(L)1 play­ers team up on CT­LA-4 in $200M deal

4 years ago
Deals
China

Bio­gen’s no good week; In­side gene edit­ing's open se­cret; No­vo Nordisk ab­sorbs RNAi part­ner; Boost­ers for all; and ...

4 years ago
Weekly

Mer­ck hits the brakes on de­vel­op­ment pro­gram as safe­ty fears trig­ger alarm

4 years ago
R&D
First page Previous page 40414243444546 Next page Last page
A service from the Financial Times